Follow us on:

Linkedin Facebook

August 29, 2025

Ampeak Energy

Ampeak Energy, updated forecasts and a growing BESS pipeline, Zeus Capital

Team plc

TEAM Plc on track with UCITS fund launch, rising revenues and advisor expansion

TEAM Plc Executive Chairman Mark Clubb outlines the launch of the company’s new UCITS fund, highlighting its role in delivering cost-efficient investment solutions and supporting international growth...
Broker Ratings

Cel-Sci Corporation (CVM) Stock Analysis: A Biotech with Over 3,000% Potential Upside

Broker Ratings

MBX Biosciences, Inc. (MBX) Investor Outlook: Analyst Ratings Suggest 164% Potential Upside

Broker Ratings

Tourmaline Bio, Inc. (TRML) Stock Analysis: Robust Buy Ratings and 144% Potential Upside Highlight Investor Appeal

Broker Ratings

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring a Potential 196.70% Upside

Broker Ratings

Autolus Therapeutics plc (AUTL) Stock Analysis: Unveiling a 512.88% Potential Upside for Bold Investors

Broker Ratings

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with Nearly 100% Upside Potential

Broker Ratings

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Growth and Challenges in the Medical Device Sector

Broker Ratings

Sage Therapeutics, Inc. (SAGE) Stock Analysis: Navigating Biotech Challenges with a 265.80% Revenue Growth

Broker Ratings

Celcuity Inc. (CELC)

Broker Ratings

Sionna Therapeutics (SION) Stock Analysis: Evaluating a 49.69% Potential Upside in Biotech Innovation

Broker Ratings

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Potential 143.68% Upside

Broker Ratings

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Unveiling a 134% Potential Upside Amidst a Biotech Breakthrough

Broker Ratings

Altimmune, Inc. (ALT) Stock Analysis: A Biotech with 363% Potential Upside

Broker Ratings

Inventiva S.A. (IVA) Stock Analysis: Exploring a 101% Potential Upside in the Biotech Sector

Broker Ratings

Keros Therapeutics, Inc. (KROS) Stock Analysis: Biotech Potential with 50% Upside Sparks Investor Interest

DirectorsTalk Interviews

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a Promising 79% Upside Potential

Broker Ratings

Xencor, Inc. (XNCR) Stock Analysis: Exploring a Biotech Gem with Over 213% Potential Upside

Broker Ratings

Verastem, Inc. (VSTM) Stock Analysis: Unpacking a 67.93% Potential Upside and Strong Buy Ratings

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

August 29, 2025

Ampeak Energy

Ampeak Energy, updated forecasts and a growing BESS pipeline, Zeus Capital

Team plc

TEAM Plc on track with UCITS fund launch, rising revenues and advisor expansion

TEAM Plc Executive Chairman Mark Clubb outlines the launch of the company’s new UCITS fund, highlighting its role in delivering cost-efficient investment solutions and supporting international growth...
Broker Ratings

Cel-Sci Corporation (CVM) Stock Analysis: A Biotech with Over 3,000% Potential Upside

Broker Ratings

MBX Biosciences, Inc. (MBX) Investor Outlook: Analyst Ratings Suggest 164% Potential Upside

Broker Ratings

Tourmaline Bio, Inc. (TRML) Stock Analysis: Robust Buy Ratings and 144% Potential Upside Highlight Investor Appeal

Broker Ratings

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring a Potential 196.70% Upside

Broker Ratings

Autolus Therapeutics plc (AUTL) Stock Analysis: Unveiling a 512.88% Potential Upside for Bold Investors

Broker Ratings

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Innovator with Nearly 100% Upside Potential

Broker Ratings

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Growth and Challenges in the Medical Device Sector

Broker Ratings

Sage Therapeutics, Inc. (SAGE) Stock Analysis: Navigating Biotech Challenges with a 265.80% Revenue Growth

Broker Ratings

Celcuity Inc. (CELC)

Broker Ratings

Sionna Therapeutics (SION) Stock Analysis: Evaluating a 49.69% Potential Upside in Biotech Innovation

Broker Ratings

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Potential 143.68% Upside

Broker Ratings

KalVista Pharmaceuticals, Inc. (KALV) Stock Analysis: Unveiling a 134% Potential Upside Amidst a Biotech Breakthrough

Broker Ratings

Altimmune, Inc. (ALT) Stock Analysis: A Biotech with 363% Potential Upside

Broker Ratings

Inventiva S.A. (IVA) Stock Analysis: Exploring a 101% Potential Upside in the Biotech Sector

Broker Ratings

Keros Therapeutics, Inc. (KROS) Stock Analysis: Biotech Potential with 50% Upside Sparks Investor Interest

DirectorsTalk Interviews

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a Promising 79% Upside Potential

Broker Ratings

Xencor, Inc. (XNCR) Stock Analysis: Exploring a Biotech Gem with Over 213% Potential Upside

Broker Ratings

Verastem, Inc. (VSTM) Stock Analysis: Unpacking a 67.93% Potential Upside and Strong Buy Ratings

Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

August 29, 2025

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple